Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC

The goal of this clinical trial is to evaluate the effectiveness and safety of a locally deployed artificial intelligence (AI) decision-support model in the multidisciplinary team (MDT) process for patients with non-small cell lung cancer (NSCLC). The main questions it aims to answer : What is the level of agreement between treatment recommendations generated by the AI model and those made by a traditional MDT? How often do clinicians modify their final treatment decision after reviewing the AI model's recommendation? Researchers will compare treatment plans from the traditional MDT (Arm 1),

Trial Details

NCT ID
NCT07626736
Phase
NA
Sponsor
Wen-zhao ZHONG
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Treat Regimen
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age ≥ 18 years;
  • MDT (Multidisciplinary Team) discussion deems a systemic treatment plan necessary;
  • Complete clinical, imaging, and molecular pathological data.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →